InvestorsHub Logo
Followers 16
Posts 1062
Boards Moderated 0
Alias Born 09/01/2019

Re: None

Thursday, 05/20/2021 10:12:19 PM

Thursday, May 20, 2021 10:12:19 PM

Post# of 44690
Thoughts I didn't post earlier...

NRX claims trademarks in this Registration.
"TRADEMARKS, TRADE NAMES AND SERVICE MARKS

BRPA," NeuroRx and their respective subsidiaries own or have rights to, and NRX Pharmaceuticals will own or have rights to, trademarks, trade names and service marks, including ZYESAMI and RLF-100, that they use in connection with the operation of their business."

The Phase 2b/3 Trial was for RLF-100 in the IV Formulation.
The Inhaler versions of NRX and RLF are both Phase 2.

RLF Must have seen this fromNRX. Also why mention the of delay in a EUA application to BRPA voting shareholders? Is it Vote YES 5-24 or lose the deal? VIRTUALY VOTE?

"This product candidate has not yet been submitted for approval and has not yet been approved by the U.S. Food and Drug Administration (“FDA”)."

NRX is saying PAY then we May deliver to BRPA? What about DATA?
RLF needs to Pay for unneeded Formulation tweaking or development from NRX?

RLF-100, Patented, IS the Drug approved for the 2b/3 Clinical Trial. NRX shysters will lose $$150M for $4M?
GEM has a LOT more Inve$ted in RLF than they do in NRX. Basically supporting Both companies. Something will be settled ASAP, IMO.
Max for NRXP deal is $35 from BRPA? Min $10? $0?. BRPA closed@ $34...GLTA...


https://ih.advfn.com/stock-market/NASDAQ/big-rock-partners-acquis-BRPA/stock-news/85169110/registration-statement-for-securities-to-be-issued#D56937DS4A_HTM_ROM56937_2